...A. We do have four marketed blockbuster products: EYLEA, EYLEA HD, DUPIXENT, and LIBTAYO now. B. It's annualizing, I think, at a rather high grade some ways in the above $14 billion. C. EYLEA net sales in 2024 were about $6 billion, up about 1%. D. We didn't have RVO submitting that this quarter. E. LIBTAYO has turned out to be another blockbuster, another $1 billion drug. F. We have a follow-on drug also in COPD, itepekimab, data later this year. G. We just announced the first and only immunotherapy to work in the adjuvant CSCC setting. H. We have our drug LAG-3 that's getting some data in metastatic melanoma. I. All of these are just 25%. J. These drugs is only 25% of our drugs that are in clinical development, and we are putting more and more in every year. K. We expect these drugs to be able to compete in market sizes, the overall market opportunity of over a couple of hundred billion dollars. L. As Len discussed, DUPIXENT was recently approved as the first-ever biologic to treat patients...
